778 related articles for article (PubMed ID: 32961800)
1. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
Lilienthal I; Herold N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961800
[TBL] [Abstract][Full Text] [Related]
2. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
3. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
5. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
6. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
Ferretti VA; León IE
Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
[TBL] [Abstract][Full Text] [Related]
7. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
8. Identification of genes contributing to cisplatin resistance in osteosarcoma cells.
Xie M; Dai H; Gu Q; Xiao C; Wang H; Lei Y; Wu C; Li X; Lin B; Li S
FEBS Open Bio; 2023 Jan; 13(1):164-173. PubMed ID: 36408691
[TBL] [Abstract][Full Text] [Related]
9. Osteosarcoma: review of the past, impact on the future. The American experience.
Jaffe N
Cancer Treat Res; 2009; 152():239-62. PubMed ID: 20213394
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.
Chen Y; Zhang K; Li Y; Guo R; Zhang K; Zhong G; He Q
J Cell Mol Med; 2019 Mar; 23(3):2115-2124. PubMed ID: 30609256
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
Hu Y; Gu J; Shen H; Shao T; Li S; Wang W; Yu Z
J Clin Lab Anal; 2020 Feb; 34(2):e23045. PubMed ID: 31642110
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of osteosarcoma].
Winkler K; Bieling P; Bielack S
Z Orthop Ihre Grenzgeb; 1992; 130(4):285-9. PubMed ID: 1413973
[TBL] [Abstract][Full Text] [Related]
13. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.
Harrison DJ; Schwartz CL
Curr Treat Options Oncol; 2017 Apr; 18(4):24. PubMed ID: 28391422
[TBL] [Abstract][Full Text] [Related]
14. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
Posthumadeboer J; van Egmond PW; Helder MN; de Menezes RX; Cleton-Jansen AM; Beliën JA; Verheul HM; van Royen BJ; Kaspers GJ; van Beusechem VW
Oncotarget; 2012 Oct; 3(10):1169-81. PubMed ID: 23045411
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
Zhang B; Zhang Y; Li R; Li J; Lu X; Zhang Y
J Orthop Surg Res; 2020 Feb; 15(1):51. PubMed ID: 32054494
[TBL] [Abstract][Full Text] [Related]
16. An update on chemotherapy for osteosarcoma.
Ferrari S; Serra M
Expert Opin Pharmacother; 2015; 16(18):2727-36. PubMed ID: 26512909
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant chemotherapy of osteosarcoma].
Yamawaki S; Isu K; Ubayama Y; Takeda N; Yagi T; Usui M; Isii S
Gan To Kagaku Ryoho; 1990 Feb; 17(2):180-8. PubMed ID: 2301948
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant chemotherapy of osteosarcoma. Preliminary results of the cooperative COSS-86 osteosarcoma study].
Bieling P; Bielack S; Delling G; Jürgens H; Kotz R; Dose C; Astheimer H; Exner G; Gadner H; Graf N
Klin Padiatr; 1991; 203(4):220-30. PubMed ID: 1942929
[TBL] [Abstract][Full Text] [Related]
19. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
Winkler K; Bieling P; Bielack S; Delling G; Dose C; Jürgens H; Kotz R; Ritter J; Salzer-Kuntschik M
Clin Orthop Relat Res; 1991 Sep; (270):79-86. PubMed ID: 1715820
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
